Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Work life after a primary diagnosis of colorectal cancer: major disruption or work as usual?

ABSTRACT: Interventions: Adult men and women Queensland residents aged 45-64 years, diagnosed with colorectal cancer and working in paid employment at the time of diagnosis. The exposure is work participation over 12 months. Primary outcome(s): Employment status, work hours and self-reported disability/limitations affecting ability to work. The outcomes are assessed via telephone and postal questionnaires using validated data items from Australian government surveys (e.g. ABS Labour Force Survey, ABS 1999 Survey of Living Standards) and the Work Productivity and Activity Impairment Questionnaire.[6 and 12 months post-diagnosis of colorectal cancer] Study Design: Purpose: Psychosocial;Duration: Longitudinal;Selection: Case control;Timing: Both

DISEASE(S): Public Health-epidemiology,Colorectal Cancer,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)

PROVIDER: 2456986 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Jung2019 - Regulating glioblastoma signaling pathways and anti-invasion therapy - core control model

Project description:This model is based on paper: Strategies in regulating glioblastoma signaling pathways and anti-invasion therapy Abstract: Glioblastoma multiforme is one of the most invasive type of glial tumors, which rapidly grows and commonly spreads into nearby brain tissue. It is a devastating brain cancer that often results in death within approximately 12 to 15 months after diagnosis. In this work, optimal control theory was applied to regulate intracellular signaling pathways of miR-451–AMPK–mTOR–cell cycle dynamics via glucose and drug intravenous administration infusions. Glucose level is controlled to activate miR-451 in the up-stream pathway of the model. A potential drug blocking the inhibitory pathway of mTOR by AMPK complex is incorporated to explore regulation of the down-stream pathway to the cell cycle. Both miR-451 and mTOR levels are up-regulated inducing cell proliferation and reducing invasion in the neighboring tissues. Concomitant and alternating glucose and drug infusions are explored under various circumstances to predict best clinical outcomes with least administration costs.

2024-09-02 | BIOMD0000000828 | BioModels

Jung2019 - egulating glioblastoma signaling pathways and anti-invasion therapy cell cycle dynamics model

Project description:This model is based on paper, based on its cell cycle dynamics model: Strategies in regulating glioblastoma signaling pathways and anti-invasion therapy Abstract: Glioblastoma multiforme is one of the most invasive type of glial tumors, which rapidly grows and commonly spreads into nearby brain tissue. It is a devastating brain cancer that often results in death within approximately 12 to 15 months after diagnosis. In this work, optimal control theory was applied to regulate intracellular signaling pathways of miR-451–AMPK–mTOR–cell cycle dynamics via glucose and drug intravenous administration infusions. Glucose level is controlled to activate miR-451 in the up-stream pathway of the model. A potential drug blocking the inhibitory pathway of mTOR by AMPK complex is incorporated to explore regulation of the down-stream pathway to the cell cycle. Both miR-451 and mTOR levels are up-regulated inducing cell proliferation and reducing invasion in the neighboring tissues. Concomitant and alternating glucose and drug infusions are explored under various circumstances to predict best clinical outcomes with least administration costs.

2024-09-02 | BIOMD0000000829 | BioModels

Gene expression profile of subcutaneous panniculitis-like T-cell Lymphoma

Project description:Gene expression profiling from skin tissue samples. Pre-treatment = sample taken before any treatment at the time of SPTL diagnosis, post-treatment 1 = sample taken during treatment after 3 to 6 months of diagnosis and post-treatment 2 = sample taken during treatment after 6 to 12 months of diagnosis.

2014-07-01 | E-MTAB-910 | biostudies-arrayexpress

Project description:Switching partners: a driving force for tree productivity in a changing environment?

| PRJNA690120 | ENA

The effect of simplified stool sampling on participation in colon cancer screening

Project description:Interventions: Participation at 12 weeks from offer of screening for colorectal cancer in the intervention group using a screening test requiring only a single stool sample to be collected for testing for occult blood. Primary outcome(s): Participation (yes or no) [At 12 weeks from postal offer of colorectal cancer screening] Study Design: Purpose: Diagnosis; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Efficacy

| 2452822 | ecrin-mdr-crc

Gene expression profile in relapsed or metastatic HNSCC patients treated with cetuximab and platinum therapy

Project description:First line chemotherapy with platinum and cetuximab is usually offered to RM-HNSCC pts. In the Extreme trial a median progression free survival (PFS) time of 5.6 months was reported. However, a small fraction of pts achieves a prolonged PFS (> than 12 months). Till now, no recognized predictive biological factor has been identified. A group of 14 cases treated with a first line platinum and cetuximab with a PFS exceeding 12 months (long PFS) and a group of 26 pts with a PFS less than 5.6 months (short PFS) were selected. The 2 groups were well balanced in regard to recognized prognostic factors (performance status, weight loss, prior radiotherapy, tumor grade, site of primary tumor, residual disease at primary tumor site). Tumor specimens of the recurrence or, if not available, of the primary tumor were collected. In order to identify molecular profiles deregulated between the 2 groups, a gene expression microarray analysis was performed using the Whole-Genome DASL assay and HumanHT-12_v4 BeadArray chips (lllumina). Gender: male=0; female=1. Age: years at diagnosis Site of primary: oral cavity=0; oropharynx=1; hypopharynx=2; larynx=3. Stage of T at first diagnosis according to AJCC 8th edition Grading according to WHO: well differentiated=1; moderately differentiated=2; scarcely differentiated=3. Radiotherapy (RT) prior to recurrence: No=0; Yes=1. Progression Free Survival (PFS): Long (>12 months); Short(<5 months).

2016-08-01 | E-GEOD-65021 | biostudies-arrayexpress

RUNX2 as a novel Biomarker for early identification of Patients Progressing to Advanced-Stage Mycosis Fungoides

Project description:Here, we used spatial transcriptomics on skin samples at time-of-diagnosis to enable prediction of patients who later progressed to advanced stages of MF. Formalin-fixed, paraffin-embedded skin biopsies at time of diagnosis from six patients with MF who progressed to advanced stages of disease within 4 months to 12 years after diagnosis, and nine patients who remained in early-stage disease over 9 to 27 years were analyzed using the GeoMx Digital Spatial Profiler to capture spatially resolved high-plex RNA gene expression data. Five different regions of interest (the epidermis, the basal layer of epidermis, CD4+ T-cells and neighboring cells, and Pautrier’s microabscesses) were profiled for further assessment.

2024-09-13 | GSE275677 | GEO

Proteome Profiling Identifies Serum Biomarkers in Rheumatoid Arthritis

Project description:Rheumatoid arthritis (RA) causes serious disability and productivity loss, and there is an urgent need for appropriate biomarkers for diagnosis, treatment assessment, and prognosis evaluation. To identify serum markers of RA, we performed mass spectrometry (MS)-based proteomics, and we obtained 24 important markers in normal and RA patient samples using a random forest machine learning model and 11 protein-protein interaction (PPI) network topological analysis methods. Re-analyze markers using additional proteomics datasets, immune infiltration status, tissue specificity, subcellular localization, correlation analysis with disease activity-based diagnostic indications, diagnostic receiver-operating characteristic analysis We discovered that ORM1 in serum is significantly differentially expressed in normal and RA patient samples, which is positively correlated with disease activity, and is closely related to CD56dim natural killer cell, effector memory CD8+ T cell and natural killer cell in the pathological mechanism, which can be better utilized for diagnosis, monitoring disease progression and efficacy assessment. This study supplies a comprehensive strategy for discovering potential serum biomarkers of RA, and provides a different perspective for comprehending the pathological mechanism of RA, identifying potential therapeutic targets, and disease management.

2022-04-19 | PXD032912 | Pride

Salmonella enterica subsp. enterica

Project description:Salmonella Typhimurium and 4,[5],12:i:- isolates from Colombia, 1999-2017

| PRJNA527650 | ENA

Study on working and daily activities affected by quality of life in colorectal patients

Project description:Primary outcome(s): QOL assessment, self-efficacy assessment, assessment of work productivity and activity impairment, and assessment of employment activities

| 2729001 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data